{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T20:14:48Z","timestamp":1775074488786,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007052","name":"Universit\u00e0 degli Studi di Verona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Many gastric cancer patients in Western countries are diagnosed as metastatic with a median overall survival of less than twelve months using standard chemotherapy. Innovative treatments, like targeted therapy or immunotherapy, have recently proved to ameliorate prognosis, but a general agreement on managing oligometastatic disease has yet to be achieved. An international multi-disciplinary workshop was held in Bertinoro, Italy, in November 2022 to verify whether achieving a consensus on at least some topics was possible.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A two-round Delphi process was carried out, where participants were asked to answer 32 multiple-choice questions about CT, laparoscopic staging and biomarkers, systemic treatment for different localization, role and indication of palliative care. Consensus was established with at least a 67% agreement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The assembly agreed to define oligometastases as a \u201cdynamic\u201d disease which either regresses or remains stable in response to systemic treatment. In addition, the definition of oligometastases was restricted to the following sites: para-aortic nodal stations, liver, lung, and peritoneum, excluding bones. In detail, the following conditions should be considered as oligometastases: involvement of para-aortic stations, in particular 16a2 or 16b1; up to three technically resectable liver metastases; three unilateral or two bilateral lung metastases; peritoneal carcinomatosis with PCI\u2009\u2264\u20096. No consensus was achieved on how to classify positive cytology, which was considered as oligometastatic by 55% of participants only if converted to negative after chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>As assessed at the time of diagnosis, surgical treatment of oligometastases should aim at R0 curativity on the entire disease volume, including both the primary tumor and its metastases. Conversion surgery was defined as surgery on the residual volume of disease, which was initially not resectable for technical and\/or oncological reasons but nevertheless responded to first-line treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10120-024-01479-5","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T13:02:19Z","timestamp":1713445339000},"page":"649-671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape"],"prefix":"10.1007","volume":"27","author":[{"given":"Paolo","family":"Morgagni","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1338-6160","authenticated-orcid":false,"given":"Maria","family":"Bencivenga","sequence":"additional","affiliation":[]},{"given":"Fatima","family":"Carneiro","sequence":"additional","affiliation":[]},{"given":"Stefano","family":"Cascinu","sequence":"additional","affiliation":[]},{"given":"Sarah","family":"Derks","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Di Bartolomeo","sequence":"additional","affiliation":[]},{"given":"Claire","family":"Donohoe","sequence":"additional","affiliation":[]},{"given":"Clarisse","family":"Eveno","sequence":"additional","affiliation":[]},{"given":"Suzanne","family":"Gisbertz","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Grimminger","sequence":"additional","affiliation":[]},{"given":"Ines","family":"Gockel","sequence":"additional","affiliation":[]},{"given":"Heike","family":"Grabsch","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Kassab","sequence":"additional","affiliation":[]},{"given":"Rupert","family":"Langer","sequence":"additional","affiliation":[]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Maltoni","sequence":"additional","affiliation":[]},{"given":"Sheraz","family":"Markar","sequence":"additional","affiliation":[]},{"given":"Markus","family":"Moehler","sequence":"additional","affiliation":[]},{"given":"Daniele","family":"Marrelli","sequence":"additional","affiliation":[]},{"given":"Maria Antonietta","family":"Mazzei","sequence":"additional","affiliation":[]},{"given":"Davide","family":"Melisi","sequence":"additional","affiliation":[]},{"given":"Carlo","family":"Milandri","sequence":"additional","affiliation":[]},{"given":"Paul Stefan","family":"Moenig","sequence":"additional","affiliation":[]},{"given":"Bianca","family":"Mostert","sequence":"additional","affiliation":[]},{"given":"Gianni","family":"Mura","sequence":"additional","affiliation":[]},{"given":"Wojciech","family":"Polkowski","sequence":"additional","affiliation":[]},{"given":"John","family":"Reynolds","sequence":"additional","affiliation":[]},{"given":"Luca","family":"Saragoni","sequence":"additional","affiliation":[]},{"given":"Mark I.","family":"Van Berge Henegouwen","sequence":"additional","affiliation":[]},{"given":"Richard","family":"Van Hillegersberg","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Vieth","sequence":"additional","affiliation":[]},{"given":"Giuseppe","family":"Verlato","sequence":"additional","affiliation":[]},{"given":"Lorena","family":"Torroni","sequence":"additional","affiliation":[]},{"given":"Bas","family":"Wijnhoven","sequence":"additional","affiliation":[]},{"given":"Guido Alberto Massimo","family":"Tiberio","sequence":"additional","affiliation":[]},{"given":"Han-Kwang","family":"Yang","sequence":"additional","affiliation":[]},{"given":"Franco","family":"Roviello","sequence":"additional","affiliation":[]},{"given":"Giovanni","family":"de Manzoni","sequence":"additional","affiliation":[]},{"name":"Bertinoro Workshop Working Group","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"1479_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1479_CR2","volume-title":"Canadian cancer statistics 2011","author":"Canadian Cancer Society\u2019s Steering Committee on Cancer Statistics","year":"2011","unstructured":"Canadian Cancer Society\u2019s Steering Committee on Cancer Statistics. Canadian cancer statistics 2011. 2011th ed. Toronto: Canadian Cancer Society; 2011.","edition":"2011"},{"key":"1479_CR3","first-page":"1479","volume":"45","author":"M Salati","year":"2019","unstructured":"Salati M, Valeri N, Spallanzani A, et al. Oligometastatic gastric cancer: an emerging clinical entity with distinct therapeutic implications. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2019;45:1479\u201382.","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"1479_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.7861\/clinmed.2022-0559","volume":"23","author":"K Nugent","year":"2023","unstructured":"Nugent K, Good J. The oligometastatic paradigm and the role of radiotherapy. Clin Med Lond Engl. 2023;23:61\u20134.","journal-title":"Clin Med Lond Engl"},{"key":"1479_CR5","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol. 2017;3:1237\u201344.","journal-title":"JAMA Oncol"},{"key":"1479_CR6","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.clinre.2020.02.003","volume":"44","author":"P Jin","year":"2020","unstructured":"Jin P, Ji X, Tian Y. Surgical management of oligometastatic disease in gastric cancer. Clin Res Hepatol Gastroenterol. 2020;44:638\u201345.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1479_CR7","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.ejso.2018.03.019","volume":"44","author":"A Carmona-Bayonas","year":"2018","unstructured":"Carmona-Bayonas A, Jim\u00e9nez-Fonseca P, Echavarria I, et al. Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry. Eur J Surg Oncol. 2018;44:1191\u20138.","journal-title":"Eur J Surg Oncol"},{"key":"1479_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12092598","volume":"12","author":"A Parisi","year":"2020","unstructured":"Parisi A, Porzio G, Ficorella C. Multimodality treatment in metastatic gastric cancer: From past to next future. Cancers. 2020;12:1\u201324.","journal-title":"Cancers"},{"key":"1479_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejca.2021.11.032","volume":"164","author":"TE Kroese","year":"2022","unstructured":"Kroese TE, van Hillegersberg R, Schoppmann S, et al. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. Eur J Cancer. 2022;164:18\u201329.","journal-title":"Eur J Cancer"},{"key":"1479_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ejca.2022.02.018","volume":"166","author":"TE Kroese","year":"2022","unstructured":"Kroese TE, van Laarhoven HWM, Nilsson M, et al. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: a systematic review and meta-analysis. Eur J Cancer. 2022;166:254\u201369.","journal-title":"Eur J Cancer"},{"key":"1479_CR11","unstructured":"University Hospital, Lille. Surgical resection plus chemotherapy versus chemotherapy alone in oligometastatic stage IV gastric cancer\u2014a multicenter, prospective, open-labeled, two-armed, randomized, controlled phase III trial. clinicaltrials.gov; 2022. Report No.: NCT03042169. https:\/\/clinicaltrials.gov\/study\/NCT03042169."},{"key":"1479_CR12","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1007\/s10120-022-01318-5","volume":"25","author":"G Roberts","year":"2022","unstructured":"Roberts G, Benusiglio PR, Bisseling T, et al. International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the life after prophylactic total gastrectomy (LAP-TG) study. Gastric Cancer. 2022;25:1094\u2013104.","journal-title":"Gastric Cancer"},{"key":"1479_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-018-0868-0","volume":"22","author":"C Mariette","year":"2019","unstructured":"Mariette C, Carneiro F, Grabsch HI, et al. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer. 2019;22:1\u20139.","journal-title":"Gastric Cancer"},{"key":"1479_CR14","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","volume":"32","author":"F Hasson","year":"2000","unstructured":"Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32:1008\u201315.","journal-title":"J Adv Nurs"},{"key":"1479_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","volume":"11","author":"P Nasa","year":"2021","unstructured":"Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: how to decide its appropriateness. World J Methodol. 2021;11:116\u201329.","journal-title":"World J Methodol"},{"key":"1479_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.semarthrit.2010.12.001","volume":"41","author":"R Nair","year":"2011","unstructured":"Nair R, Aggarwal R, Khanna D. Methods of formal consensus in classification\/diagnostic criteria and guideline development. Semin Arthritis Rheum. 2011;41:95\u2013105.","journal-title":"Semin Arthritis Rheum"},{"key":"1479_CR17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"1479_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000531590","volume":"46","author":"M Hingorani","year":"2023","unstructured":"Hingorani M, Stubley H. Management of oligometastatic disease in esophagogastric cancer: what is the evidence? Oncol Res Treat. 2023;46:312\u20139.","journal-title":"Oncol Res Treat"},{"issue":"185","key":"1479_CR19","first-page":"28","volume":"2023","author":"TE Kroese","year":"1990","unstructured":"Kroese TE, van Laarhoven HWM, Schoppman SF, et al. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: a delphi consensus study in Europe. Eur J Cancer Oxf Engl. 1990;2023(185):28\u201339.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"1479_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11864-022-01042-3","volume":"24","author":"K Beyer","year":"2023","unstructured":"Beyer K. Surgery matters: progress in surgical management of gastric cancer. Curr Treat Options Oncol. 2023;24:108\u201329.","journal-title":"Curr Treat Options Oncol"},{"key":"1479_CR21","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1186\/s12885-017-3918-9","volume":"17","author":"S-E Al-Batran","year":"2017","unstructured":"Al-Batran S-E, Goetze TO, Mueller DW, et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction\u2014a phase III trial of the German AIO\/CAO-V\/CAOGI. BMC Cancer. 2017;17:893.","journal-title":"BMC Cancer"},{"key":"1479_CR22","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s12029-020-00436-6","volume":"52","author":"AH Wani","year":"2021","unstructured":"Wani AH, Parry AH, Feroz I, et al. Preoperative staging of gastric cancer using computed tomography and its correlation with histopathology with emphasis on multi-planar reformations and virtual gastroscopy. J Gastrointest Cancer. 2021;52:606\u201315.","journal-title":"J Gastrointest Cancer"},{"key":"1479_CR23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1148\/radiol.2422051557","volume":"242","author":"CY Chen","year":"2007","unstructured":"Chen CY, Hsu JS, Wu DC, et al. Gastric cancer: preoperative local staging with 3D multi-detector row CT\u2013correlation with surgical and histopathologic results. Radiology. 2007;242:472\u201382.","journal-title":"Radiology"},{"key":"1479_CR24","first-page":"20","volume":"20","author":"G De Manzoni","year":"2017","unstructured":"De Manzoni G, Marrelli D, Baiocchi GL, et al. The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2017;20:20\u201330.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"1479_CR25","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1007\/s00330-021-08205-0","volume":"32","author":"MA Mazzei","year":"2022","unstructured":"Mazzei MA, Bagnacci G, Gentili F, et al. Structured and shared CT radiological report of gastric cancer: a consensus proposal by the Italian Research Group for Gastric Cancer (GIRCG) and the Italian Society of Medical and Interventional Radiology (SIRM). Eur Radiol. 2022;32:938\u201349.","journal-title":"Eur Radiol"},{"key":"1479_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.5340","volume":"156","author":"EC Gertsen","year":"2021","unstructured":"Gertsen EC, Brenkman HJF, van Hillegersberg R, et al. 18F-fludeoxyglucose-positron emission tomography\/computed tomography and laparoscopy for staging of locally advanced gastric cancer: a multicenter prospective dutch cohort study (PLASTIC). JAMA Surg. 2021;156: e215340.","journal-title":"JAMA Surg"},{"key":"1479_CR27","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.21037\/qims-20-683","volume":"11","author":"MA Mazzei","year":"2021","unstructured":"Mazzei MA, Di Giacomo L, Bagnacci G, et al. Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer-a multicenter study of GIRCG (Italian Research Group for Gastric Cancer). Quant Imaging Med Surg. 2021;11:2376\u201387.","journal-title":"Quant Imaging Med Surg"},{"key":"1479_CR28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.21037\/qims.2018.07.08","volume":"8","author":"MA Mazzei","year":"2018","unstructured":"Mazzei MA, Nardone V, Di GL, et al. The role of delta radiomics in gastric cancer. Quant Imaging Med Surg. 2018;8:719\u201321.","journal-title":"Quant Imaging Med Surg"},{"key":"1479_CR29","doi-asserted-by":"publisher","first-page":"1794524","DOI":"10.1155\/2018\/1794524","volume":"2018","author":"MA Mazzei","year":"2018","unstructured":"Mazzei MA, Bagnacci G, Gentili F, et al. Gastric cancer maximum tumour diameter reduction rate at CT examination as a radiological index for predicting histopathological regression after neoadjuvant treatment: a multicentre GIRCG study. Gastroenterol Res Pract. 2018;2018:1794524.","journal-title":"Gastroenterol Res Pract"},{"key":"1479_CR30","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005\u201320.","journal-title":"Ann Oncol"},{"key":"1479_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13061304","volume":"13","author":"L Fornaro","year":"2021","unstructured":"Fornaro L, Spallanzani A, de Vita F, et al. Beyond the guidelines: The grey zones of the management of gastric cancer. Consensus statements from the gastric cancer Italian network (gain). Cancers. 2021;13:1\u201342.","journal-title":"Cancers"},{"key":"1479_CR32","first-page":"1","volume":"24","author":"Japanese Gastric Cancer Association","year":"2021","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2021;24:1\u201321.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc."},{"key":"1479_CR33","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.6004\/jnccn.2016.0137","volume":"14","author":"JA Ajani","year":"2016","unstructured":"Ajani JA, D\u2019Amico TA, Almhanna K, et al. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2016;14:1286\u2013312.","journal-title":"J Natl Compr Cancer Netw JNCCN."},{"key":"1479_CR34","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/his.14059","volume":"76","author":"B Dislich","year":"2020","unstructured":"Dislich B, Blaser N, Berger MD, et al. Preservation of Epstein\u2013Barr virus status and mismatch repair protein status along the metastatic course of gastric cancer. Histopathology. 2020;76:740\u20137.","journal-title":"Histopathology"},{"key":"1479_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"AJ Bass","year":"2014","unstructured":"Bass AJ, Thorsson V, Shmulevich I, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202\u20139.","journal-title":"Nature"},{"key":"1479_CR36","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1158\/2159-8290.CD-19-0487","volume":"9","author":"AK Nagaraja","year":"2019","unstructured":"Nagaraja AK, Kikuchi O, Bass AJ. Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma. Cancer Discov. 2019;9:1656\u201372.","journal-title":"Cancer Discov"},{"key":"1479_CR37","first-page":"379","volume":"20","author":"SR Markar","year":"2017","unstructured":"Markar SR, Mackenzie H, Mikhail S, et al. Surgical resection of hepatic metastases from gastric cancer: outcomes from national series in England. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2017;20:379\u201386.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"1479_CR38","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s13304-018-0536-2","volume":"70","author":"S Ministrini","year":"2018","unstructured":"Ministrini S, Solaini L, Cipollari C, et al. Surgical treatment of hepatic metastases from gastric cancer. Updat Surg. 2018;70:273\u20138.","journal-title":"Updat Surg"},{"issue":"179","key":"1479_CR39","first-page":"65","volume":"2023","author":"TE Kroese","year":"1990","unstructured":"Kroese TE, Takahashi Y, Lordick F, et al. Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study. Eur J Cancer Oxf Engl. 1990;2023(179):65\u201375.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"1479_CR40","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/bjs.9484","volume":"101","author":"A Tsuburaya","year":"2014","unstructured":"Tsuburaya A, Mizusawa J, Tanaka Y, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653\u201360.","journal-title":"Br J Surg"},{"key":"1479_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"S Article","year":"2023","unstructured":"Article S. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1\u201325.","journal-title":"Gastric Cancer"},{"key":"1479_CR42","first-page":"319","volume":"23","author":"I Yasufuku","year":"2020","unstructured":"Yasufuku I, Nunobe S, Ida S, et al. Conversion therapy for peritoneal lavage cytology-positive type 4 and large type 3 gastric cancer patients selected as candidates for R0 resection by diagnostic staging laparoscopy. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2020;23:319\u201327.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"1479_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10120-014-0388-5","volume":"18","author":"CS Cabalag","year":"2015","unstructured":"Cabalag CS, Chan STF, Kaneko Y, et al. A systematic review and meta-analysis of gastric cancer treatment in patients with positive peritoneal cytology. Gastric Cancer. 2015;18:11\u201322.","journal-title":"Gastric Cancer"},{"key":"1479_CR44","first-page":"228","volume":"8","author":"EWL Chuwa","year":"2005","unstructured":"Chuwa EWL, Khin L-W, Chan W-H, et al. Prognostic significance of peritoneal lavage cytology in gastric cancer in Singapore. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2005;8:228\u201337.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"1479_CR45","first-page":"61","volume":"15","author":"S Satoh","year":"2012","unstructured":"Satoh S, Okabe H, Teramukai S, et al. Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2012;15:61\u20139.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"1479_CR46","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1245\/s10434-019-07229-7","volume":"26","author":"H Okabe","year":"2019","unstructured":"Okabe H, Hata H, Hosogi H, et al. A phase 2 study of induction chemotherapy using docetaxel, cisplatin, and S-1 for gastric cancer with peritoneal metastasis (KUGC06). Ann Surg Oncol. 2019;26:1779\u201386.","journal-title":"Ann Surg Oncol"},{"key":"1479_CR47","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10120-023-01363-8","volume":"26","author":"T Yamaguchi","year":"2023","unstructured":"Yamaguchi T, Takashima A, Nagashima K, et al. Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study. Gastric Cancer. 2023;26:307\u201316.","journal-title":"Gastric Cancer"},{"key":"1479_CR48","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","volume":"17","author":"O Glehen","year":"2010","unstructured":"Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:2370\u20137.","journal-title":"Ann Surg Oncol"},{"key":"1479_CR49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4251\/wjgo.v2.i2.85","volume":"2","author":"Y Yonemura","year":"2010","unstructured":"Yonemura Y, Elnemr A, Endou Y, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. 2010;2:85.","journal-title":"World J Gastrointest Oncol."},{"key":"1479_CR50","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1245\/s10434-015-5081-3","volume":"23","author":"CS Chia","year":"2016","unstructured":"Chia CS, You B, Decullier E, et al. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol. 2016;23:1971\u20139.","journal-title":"Ann Surg Oncol"},{"key":"1479_CR51","first-page":"109","volume":"37","author":"TE Kroese","year":"2022","unstructured":"Kroese TE, Jorritsma NKN, van Laarhoven HWM, et al. Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: a nationwide population-based cohort study. Clin Transl Radiat Oncol. 2022;37:109\u201315.","journal-title":"Clin Transl Radiat Oncol"},{"key":"1479_CR52","first-page":"329","volume":"19","author":"K Yoshida","year":"2016","unstructured":"Yoshida K, Yamaguchi K, Okumura N, et al. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2016;19:329\u201338.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"1479_CR53","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ags3.12515","volume":"6","author":"K Yoshida","year":"2021","unstructured":"Yoshida K, Yasufuku I, Terashima M, et al. International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg. 2021;6:227\u201340.","journal-title":"Ann Gastroenterol Surg"},{"key":"1479_CR54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet Lond Engl. 2021;398:27\u201340.","journal-title":"Lancet Lond Engl"},{"key":"1479_CR55","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","volume":"603","author":"K Shitara","year":"2022","unstructured":"Shitara K, Ajani JA, Moehler M, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603:942\u20138.","journal-title":"Nature"},{"key":"1479_CR56","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet Lond Engl. 2010;376:687\u201397.","journal-title":"Lancet Lond Engl"},{"key":"1479_CR57","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Ya\u00f1ez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600:727\u201330.","journal-title":"Nature"},{"key":"1479_CR58","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang Y-J, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419\u201330.","journal-title":"N Engl J Med"},{"key":"1479_CR59","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","volume":"17","author":"K Fujitani","year":"2016","unstructured":"Fujitani K, Yang H-K, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309\u201318.","journal-title":"Lancet Oncol"},{"key":"1479_CR60","first-page":"10","volume":"21","author":"S Jamel","year":"2018","unstructured":"Jamel S, Markar SR, Malietzis G, et al. Prognostic significance of peritoneal lavage cytology in staging gastric cancer: systematic review and meta-analysis. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2018;21:10\u20138.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"1479_CR61","first-page":"1261","volume":"42","author":"F Coccolini","year":"2016","unstructured":"Coccolini F, Catena F, Glehen O, et al. Effect of intraperitoneal chemotherapy and peritoneal lavage in positive peritoneal cytology in gastric cancer. Systematic review and meta-analysis. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2016;42:1261\u20137.","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol."},{"key":"1479_CR62","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37:2028\u201340.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1479_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5640-2","author":"WJ Koemans","year":"2019","unstructured":"Koemans WJ, Van Der Kaaij RT, Boot H, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II). BMC Cancer. 2019. https:\/\/doi.org\/10.1186\/s12885-019-5640-2.","journal-title":"BMC Cancer"},{"key":"1479_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08872-8","author":"TO G\u00f6tze","year":"2021","unstructured":"G\u00f6tze TO, Piso P, Lorenzen S, et al. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II\/III adenocarcinoma\u2014the phase III \u201cPREVENT\u201d\u2014(FLOT9) trial of the AIO\/CAOGI \/ACO. BMC Cancer. 2021. https:\/\/doi.org\/10.1186\/s12885-021-08872-8.","journal-title":"BMC Cancer"},{"key":"1479_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-183","author":"O Glehen","year":"2014","unstructured":"Glehen O, Passot G, Villeneuve L, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer. 2014. https:\/\/doi.org\/10.1186\/1471-2407-14-183.","journal-title":"BMC Cancer"},{"key":"1479_CR66","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.ejso.2015.04.021","volume":"41","author":"J Kinoshita","year":"2015","unstructured":"Kinoshita J, Fushida S, Tsukada T, et al. Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer. Eur J Surg Oncol. 2015;41:1354\u201360.","journal-title":"Eur J Surg Oncol"},{"key":"1479_CR67","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang Y-J, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet Lond Engl. 2023;401:1655\u201368.","journal-title":"Lancet Lond Engl."},{"key":"1479_CR68","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133\u201341.","journal-title":"Nat Med"},{"key":"1479_CR69","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet Lond Engl. 2023;402:2197\u2013208.","journal-title":"Lancet Lond Engl"},{"key":"1479_CR70","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh D-Y, Ya\u00f1ez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181\u201395.","journal-title":"Lancet Oncol"},{"key":"1479_CR71","unstructured":"ESMO Congress 2023. https:\/\/www.esmo.org\/meeting-calendar\/past-meetings\/esmo-congress-2023."}],"updated-by":[{"DOI":"10.1007\/s10120-024-01520-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000}}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-024-01479-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-024-01479-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-024-01479-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T15:02:16Z","timestamp":1719068536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-024-01479-5"}},"subtitle":["Bertinoro Workshop, November 2022"],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1479"],"URL":"https:\/\/doi.org\/10.1007\/s10120-024-01479-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10120-024-01520-7","asserted-by":"object"}]},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"2 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10120-024-01520-7","URL":"https:\/\/doi.org\/10.1007\/s10120-024-01520-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}